KURA
What one share of Kura Oncology holds
Pharmaceutical Preparations
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates.
Kura Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.87 |
|---|---|
| Profit | −$3.36 |
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.33 |
| Cash and investments | $0.79 |
| Debt | $0.11 |
| Book value | $0.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.47 | — | −$1.36 | — | $2.94 |
| 2017 | — | −$1.52 | — | −$1.22 | — | $2.71 |
| 2018 | — | −$1.72 | — | −$1.38 | — | $4.22 |
| 2019 | — | −$1.51 | — | −$1.31 | — | $4.82 |
| 2020 | — | −$1.69 | $0.04 | −$1.36 | — | $9.23 |
| 2021 | — | −$1.97 | $0.02 | −$1.59 | — | $7.61 |
| 2022 | — | −$2.03 | $0.01 | −$1.65 | — | $6.15 |
| 2023 | $0.00 | −$2.08 | $0.00 | −$1.71 | — | $5.34 |
| 2024 | $0.63 | −$2.02 | $0.01 | $1.55 | — | $5.29 |
| 2025 | $0.77 | −$3.18 | $0.08 | −$0.81 | — | $1.98 |